

Ref:Corp.Sec/2025-26/BSE/34

Dated:03.06.2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai-400001

SCRIPTCODE:524703

Dear Sir/Ma'am,

Sub: Intimation in respect of the Show cause notice Received from Government Of Maharashtra Department Of Goods And Service Tax Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


Pursuant to the provisions of Regulation 30 read with sub-para 20 of Para A of Part A of Schedule III of the Listing Regulations, we hereby submit that the Company is in receipt of Show cause notice under section 73(1) of the Maharashtra Goods & Services Tax Act, 2017 (MGST Act, 2017)[See Rule 142 of the Maharashtra Goods & Services Tax Rules, 2017]passed by the Government Of Maharashtra Department Of Goods And Service Tax Intimation of liability under section 73(5).

The details of above Show cause Notice are given below:

This is for your information and appropriate dissemination.

Thanking you,

Yoursfaithfully,
For. Sandu Pharmaceuticals Limited



PratikaMhambray
Company Secretary and Compliance Officer
A36512

Encl.:AsAbove



SANDU PHARMACEUTICALS LIMITED

CIN:L24233GA1985PLC001587

Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.

Tel: +91 832 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in

ANNEXURE-A

Name of the Authority	Government Of Maharashtra Department Of Goods And Service Tax-Office Of The Deputy Commissioner Of State Tax
Nature and details of the action(s) taken, initiated or order(s) passed	Show cause notice under section 73(1) of the Maharashtra Goods & Services Tax Act, 2017(MGST Act, 2017) [See Rule 142 of the Maharashtra Goods & Services Tax Rules, 2017]
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the Authority;	31-05-2025
Details of the violation(s)/contravention (s) committed or alleged to be committed;	Show cause notice received for Excess ITC claimed in GSTR3B/9 which is not confirmed in GSTR2A/8A, ITC received on Invoices from RC cancelled suppliers, Less RCM liability paid in GSTR3B/9 as compared to shown by suppliers in GSTR1 Total Rs.96,48,544/-(Including Interest & penalty)
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	The Company shall be filling reply to authority on the show cause notice issued to Company. As per Company's own assessment and also based on legal advice, management is confident of favourable outcome for such reply/appeal if any. Company is hopeful of a favourable outcome thereof and the Company does not expect the said order to have any impact on financial, operation or other activities of the Company.
Remarks	NA

For Sandu Pharmaceuticals Limited

VIJAY KAJAREKAR
CFO



AN ISO 9001:2015 CERTIFIED ORGANISATION

Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.

Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in

